Transenterix Inc (TRXC)

4.08  -0.46 (-10.13%)

After market: 3.79 -0.29 (-7.11%)

News Image
3 years ago - InvestorPlace

Only Patience Will Be Rewarded With Asensus

If you're interested in Asensus and TRXC stock, be prepared to invest time and money. It will take 5 years to know if you have a winner here.

News Image
3 years ago - PennyStocks.com

Best Penny Stocks To Buy After A Pullback? 3 To Watch Right Now

Hot Penny Stocks To Add To Your Watch List This Week

News Image
3 years ago - InvestorPlace

TRXC Stock: Why Medical Device Play Asensus Surgical Is Soaring Today

Shares of TRXC stock are rising on Wednesday after the firm received general surgery clearance from the FDA for its Senhance Surgical System.

News Image
3 years ago - InvestorPlace

TransEnterix Has a Lesson That Reddit Investors Should Take Time to Learn

TRXC stock is an example of what to look for in low-priced stocks

News Image
3 years ago - Zacks Investment Research

TransEnterix (TRXC) Flat As Market Gains: What You Should Know

TransEnterix (TRXC) closed at $3.72 in the latest trading session, marking no change from the prior day.

News Image
3 years ago - The Motley Fool

Is TransEnterix a Good Stock to Buy Now?

Shares of the robotic surgical-system manufacturer are soaring, but can this company become the next Intuitive Surgical?

News Image
3 years ago - InvestorPlace

A ‘Reddit Rally’ Doesn’t Make TransEnterix a Long-Term Buy

TRXC stock has struggled badly since its 2014 IPO. A trader-driven rally is unlikely to change the concerning long-term trend.

News Image
3 years ago - InvestorPlace

Make a Surgical Strike With TransEnterix Stock

As TRXC stock takes a breather amid a sustained uptrend, investors should consider owning shares of this medical robotics innovator.

News Image
3 years ago - InvestorPlace

Here’s a Second Opinion For Those Considering Entering Transenterix Stock

Though it’s got much enthusiasmbehind it, TRXC stock is risky because of its “meme” trade qualities.

News Image
3 years ago - Zacks Investment Research

Is TransEnterix (TRXC) Outperforming Other Medical Stocks This Year?

Is (TRXC) Outperforming Other Medical Stocks This Year?

News Image
3 years ago - Zacks Investment Research

Here's Why Momentum Investors Will Love TransEnterix (TRXC)

Does TransEnterix (TRXC) have what it takes to be a top stock pick for momentum investors? Let's find out.

News Image
3 years ago - TransEnterix, Inc.

TransEnterix Announces New Training Center in EU

News Image
3 years ago - InvestorPlace

TransEnterix Doesn’t Have What It Takes to Be a Long-Term Investment

TransEnterix is facing competition from much larger companies, while its revenue is quite low. Investors should take profits on TRXC stock.TRXC Stock Doesn't Have What It Takes to Be a Long-Term Investment

News Image
3 years ago - InvestorPlace

TransEnterix Stock Has Potential, But Wait for a Pullback

Given its notable stumble a few years back, it may be wise to exercise some caution before buying robotic surgery play TRXC stock

News Image
3 years ago - BusinessInsider

Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027

Palm Beach, Fl., Feb. 11, 2021 /PRNewswire/ -- Cardiovascular devices are the medical devices which are used to diagnosis and treat the heart dise...

News Image
3 years ago - Financialnewsmedia.com

Global Cardiovascular Devices Market Now Project to Exceed $71 Billion By 2027

Financialnewsmedia.com News Commentary

News Image
3 years ago - InvestorPlace

With $90 Million in Cash in the Bank, TransEnterix Should Survive

TRXC stock will do well over time, now that the company is well-capitalized. But does that mean it's a good time for new investors to hop on?

News Image
3 years ago - PennyStocks.com

Best Penny Stock To Buy Next Week? 5 Biotechs You Might’ve Missed

Are These Biotech Penny Stocks On Next Week's Watch List?

News Image
3 years ago - The Motley Fool

These 2 Growth Stocks Can Become Money Machines in the Next 5 Years

One robotic surgery company and one cybersecurity specialist are bound to impress in the long run.